Table 1.

CD3⁻ CD16⁺, CD3⁻ CD56⁺, CD3⁻ CD16⁺ CD56⁺ NK cells, CD3⁺ CD56⁺ NKT cells, and CD5⁺ CD19⁺ B cells percentage, IL-10 serum levels in IFN-treated RRMS, IFN-treated MS, NMOSD and HC groups

Variables	IFN-treated RR MS [15]	Untreated RR MS [15]	NMOSD [15]	HC [30]	P value
CD3−CD16+ CD56+	1.81 $\pm$ 0.87	4.74 $\pm$ 1.80	4.64 $\pm$ 1.26	5.83 $\pm$ 2.19	< 0.0001
CD3−CD16+	3.13 $\pm$ 1.49	7.62 $\pm$ 3.23	5.91 $\pm$ 2.50	8.28 $\pm$ 3.85	< 0.0001
CD3−CD56+	4.73 $\pm$ 2.63	13.31 $\pm$ 5.67	11.23 $\pm$ 4.76	13.49 $\pm$ 7.51	< 0.0007
CD3+CD56+	2.89 $\pm$ 1.51	5.56 $\pm$ 3.04	5.47 $\pm$ 1.24	3.16 $\pm$ 1.98	< 0.002
CD5+CD19+ B cell	0.81 $\pm$ 0.17	1.32 $\pm$ 0.67	0.30 $\pm$ 0.20	0.5 $\pm$ 0.22	< 0.0001
Serum level of IL-10 (pg/ml)	8.06 $\pm$ 5.39	5.07 $\pm$ 1.44	5.33 $\pm$ 2.56	8.38 $\pm$ 2.84	< 0.003
Total number of attack in first two year	1.89(1–4)	2.5(1–5)	2.01(1–4)	–	N.S
Disease duration	5.6(0.4–13)	2.6(0.1–10)	6.6(1–17)	–	0.04
Age of disease onset	29.8(16–56)	25.6(12–44)	30.8(19–42)	–	N.S

Values indicate mean $\pm$ SD. The values of three last parameters show mean (min–max). The flow cytometric result are shown as percentage

IFN-treated interferon-β treated, RRMs relapsing remitting multiple sclerosis, NMOSD neuromyelitis optica spectrum disorder, HC healthy control, NK natural killer, IL-10 interleukin 10